We offer a comprehensive suite of immune checkpoint-related products, including high-quality proteins, inhibitor screening ...

Immune checkpoint blockade is one of the major advances in cancer treatment in recent years. However, the majority of immune checkpoints are embedded in the cell membrane and this fact represents a ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

Georgia Tech researchers have developed biosensors with advanced sleuthing skills and the technology may revolutionize cancer ...

Immunotherapy, particularly immune checkpoint blockade, has revolutionized cancer treatment. By targeting proteins like PD-1 and CTLA-4, these therapies unleash the immune system’s natural ...

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the ...

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...

An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...

and mechanisms of immune regulation. A strength of the program is the ability to translate laboratory findings into effective clinical applications. Scientists from our program have played a central ...